Arvind Goel1, Sarosh Rana. 1. aDivision of Nephrology/Department of Medicine bMaternal Fetal Medicine/Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: The review summarizes new observations of key roles for circulating angiogenic factors in diagnosing, managing, and treating preeclampsia. RECENT FINDINGS: Alterations in circulating angiogenic factors (soluble fms-like tyrosine kinase-1 and placental growth factor) in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). Measurement of these angiogenic biomarkers further helps differentiate preeclampsia and its complications from other disorders that present with similar clinical profiles. A ratio of soluble fms-like tyrosine kinase-1/placental growth factor greater than 85 appears ideal as the cut-off for both diagnosis and prognosis. There is also evidence that modulating these factors has therapeutic effects, suggesting a future role for angiogenic factors in treatment and prevention of preeclampsia. SUMMARY: Circulating angiogenic biomarkers help in diagnostic and prognostic profiling of preeclampsia and may facilitate better management of these patients.
PURPOSE OF REVIEW: The review summarizes new observations of key roles for circulating angiogenic factors in diagnosing, managing, and treating preeclampsia. RECENT FINDINGS: Alterations in circulating angiogenic factors (soluble fms-like tyrosine kinase-1 and placental growth factor) in preeclampsia correlate with the diagnosis and adverse outcomes, particularly when the disease presents prematurely (<34 weeks). Measurement of these angiogenic biomarkers further helps differentiate preeclampsia and its complications from other disorders that present with similar clinical profiles. A ratio of soluble fms-like tyrosine kinase-1/placental growth factor greater than 85 appears ideal as the cut-off for both diagnosis and prognosis. There is also evidence that modulating these factors has therapeutic effects, suggesting a future role for angiogenic factors in treatment and prevention of preeclampsia. SUMMARY: Circulating angiogenic biomarkers help in diagnostic and prognostic profiling of preeclampsia and may facilitate better management of these patients.
Authors: Tejas V Patel; Jeffrey A Morgan; George D Demetri; Suzanne George; Robert G Maki; Michael Quigley; Benjamin D Humphreys Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Richard J Levine; Chun Lam; Cong Qian; Kai F Yu; Sharon E Maynard; Benjamin P Sachs; Baha M Sibai; Franklin H Epstein; Roberto Romero; Ravi Thadhani; S Ananth Karumanchi Journal: N Engl J Med Date: 2006-09-07 Impact factor: 91.245
Authors: Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Sarosh Rana; Camille E Powe; Saira Salahuddin; Stefan Verlohren; Frank H Perschel; Richard J Levine; Kee-Hak Lim; Julia B Wenger; Ravi Thadhani; S Ananth Karumanchi Journal: Circulation Date: 2012-01-18 Impact factor: 29.690
Authors: Piya Chaemsaithong; Roberto Romero; Adi L Tarca; Steven J Korzeniewski; Alyse G Schwartz; Jezid Miranda; Ahmed I Ahmed; Zhong Dong; Sonia S Hassan; Lami Yeo; Tinnakorn Tinnakorn Journal: J Matern Fetal Neonatal Med Date: 2014-09-29
Authors: N'Dea S Irvin-Choy; Katherine M Nelson; Megan N Dang; Jason P Gleghorn; Emily S Day Journal: Nanomedicine Date: 2021-06-17 Impact factor: 6.096
Authors: Rayana Leal Luna; Vanessa R Kay; Matthew T Rätsep; Kasra Khalaj; Mallikarjun Bidarimath; Nichole Peterson; Peter Carmeliet; Albert Jin; B Anne Croy Journal: Mol Hum Reprod Date: 2015-12-07 Impact factor: 4.025